Prevalence of polymorphic variants of FcγRIIIa, FcγRIIa, and FcγRIIb, based on available literature
| Total number of subjects (N) | Subject characteristics | FcγRIIIa-158 (CD16A-158) | |||||||||
| VV (high affinity) | VF | FF (low affinity) | V carriers | F carriers | |||||||
| n | % | n | % | n | % | n | % | n | % | ||
| 6961 (across 21 studies)44–64 | Healthy; with cancer | 846 | 12% | 3110 | 45% | 3005 | 43% | 3956 | 57 | 6115 | 88 |
| Total number of subjects (N) | Subject characteristics | FcγRIIa-131 (CD32A-131) | |||||||||
| HH (high affinity) | HR | RR (low affinity) | H carriers | R carriers | |||||||
| n | % | n | % | n | % | n | % | n | % | ||
| 4491 (across 11 studies)44 45 49 50 54–56 58 65–67 | Caucasians; Blacks | 1199 | 27% | 634 | 14% | 1081 | 24% | 1833 | 41 | 1715 | 38 |
| 563 (across four studies)48 59 60 62 | Asians | 337 | 60% | 194 | 35% | 32 | 6% | 531 | 94 | 226 | 40 |
| Total number of subjects (N) | Subject characteristics | FcγRIIb-232 (CD32B-232) | |||||||||
| II (functional allele) | TI | TT (impaired allele) | I carriers | T carriers | |||||||
| n | % | n | % | n | % | n | % | n | % | ||
| 3390 (across six studies)54 56 58 68–70 | Caucasians | 2666 | 79% | 669 | 20% | 55 | 2% | 3335 | 98 | 724 | 21 |
| 2315 (across seven studies)48 56 68 70–73 | Asians; Blacks | 1300 | 56% | 868 | 38% | 147 | 6% | 2168 | 94 | 1015 | 44 |
FcγR, fragment crystallizable gamma receptor.